Contrast Media & Molecular Imaging / 2018 / Article / Fig 1

Research Article

Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage

Figure 1

Transverse prostate MR images from a 69-year-old male patient with biopsy proven prostate cancer (Gleason score 3 + 4 and serum PSA 6.6 ng/mL): (a) T2-weighted image showing in the transitional zone a hypointense area without clear border; (b) ADC map: transitional zone hypointense region with a clear border, with ADC value of 0.75 × 10−3 mm2/s; (c) T1-weighted image early enhancement map: the enhanced region of interest 1 (ROI1, red line) corresponds to the tumor, and ROI 2 (green line) was selected from normal prostate tissue as healthy control; (d) Ktrans map: ROI 1 Ktrans 0.120 min−1 and ROI 2 Ktrans 0.048 min−1; (e) Kep map: ROI 1 Kep 0.657 min−1 and ROI 2 Kep 0.327 min−1; (f) iAUC map: ROI 1 iAUC 14.976 mmoL/L/min and ROI 2 iAUC 6.871 mmoL/L/min; (g) enhancement kinetics pattern from the two ROIs: the time-intensity curves were obtained from dynamic contrast-enhanced MRI. ROI1 showing a higher peak enhancement and an early wash-in and wash-out of contrast medium compared with ROI 2.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.